<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002271</url>
  </required_header>
  <id_info>
    <org_study_id>054A</org_study_id>
    <secondary_id>81-1</secondary_id>
    <nct_id>NCT00002271</nct_id>
  </id_info>
  <brief_title>An Ascending, Single Oral Dose Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects</brief_title>
  <official_title>An Ascending, Single Oral Dose Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lederle Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To characterize the pharmacokinetics of orally administered 3'-deoxy-3'-fluorothymidine&#xD;
      (FLT), in a liquid formulation, after single doses in asymptomatic HIV-infected patients and&#xD;
      to assess the safety and tolerance of the single oral doses of FLT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Oral candida infection documented by morphology or by response to antifungal therapy&#xD;
             within 2 months prior to study entry.&#xD;
&#xD;
          -  Temperature &gt; 37.8 degrees Centigrade.&#xD;
&#xD;
          -  Malignancy other than cutaneous basal cell carcinoma or cervical carcinoma in situ.&#xD;
&#xD;
          -  Significant chronic underlying medical illnesses which would prevent continuous&#xD;
             participation in this clinical trial.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        -&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Significant chronic underlying medical illnesses which would prevent continuous&#xD;
             participation in this clinical trial.&#xD;
&#xD;
          -  Unwilling to sign informed consent.&#xD;
&#xD;
          -  Intolerant to zidovudine (AZT).&#xD;
&#xD;
          -  Oral hairy leukoplakia at any time prior to study entry.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 7 days of study entry:&#xD;
&#xD;
          -  Antiretroviral drugs.&#xD;
&#xD;
          -  Immunomodulators.&#xD;
&#xD;
          -  Excluded within 30 days of study entry:&#xD;
&#xD;
          -  Any investigational drugs.&#xD;
&#xD;
        Patients have the following:&#xD;
&#xD;
          -  HIV seropositivity by licensed ELISA test, confirmed by Western Blot analysis.&#xD;
&#xD;
          -  No symptoms as defined by:&#xD;
&#xD;
               1. Normal neurological exam.&#xD;
&#xD;
               2. Absence of the following:&#xD;
&#xD;
          -  Unintentional weight loss of greater than 10 pounds or more than 10 percent of usual&#xD;
             body weight within 2 months prior to study entry.&#xD;
&#xD;
          -  Unexplained temperature &gt; 37.8 C on more than 5 consecutive days or on more than 10&#xD;
             days in any 30 day period in the one month prior to expected study entry.&#xD;
&#xD;
          -  Unexplained diarrhea defined by = or &gt; 3 liquid stools per day persisting &gt; 7 days&#xD;
             within 2 months prior to expected study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Johns Hopkins Hosp</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 1991</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Thymidine</keyword>
  <keyword>Nucleosides</keyword>
  <keyword>Antiviral Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alovudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

